Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Schedule of Consolidated Statements of Operations

Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s consolidated statements of operations, regularly reviewed by the Company’s CODM, include salaries and clinical trials expenses and presented below.

		Three months ended								Six months ended
		June 30								June 30
		2026				2025				2026				2025

Revenues from defense business			332				-				332				-
Cost of revenues			235				-				235				-
Gross profit			97				-				97				-

Operating expenses:
Salaries and related expenses, other than share-based compensation			429				1,932				2,202				3,909
Clinical trials			-				3,424				95				7,049
Stock based compensation			3,988				696				2,060				1,355
Depreciation expenses			4				292				4				528
Insurance			623				-				1,466				-
Other segment items (*)			370				1,089				883				2,348
Total Operating loss			5,414				7,433				6,710				15,189

(*)

Other segment items include all remaining costs necessary to operate the Company’s business, which primarily include external professional services, rent and other administrative expenses, and are presented net of grants received

Schedule of Revenues From External Customers and Long Lived Assets

The Company’s Property and equipment, as well as the Company’s operating lease right-of-use assets recognized on the consolidated balance sheets were located as follows:

		As of June 30, 2026				As of December 31, 2025

Israel			99				157
United States			2				-
Total			101				157